Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before
- PMID: 1664344
- DOI: 10.1007/BF00218669
Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before
Abstract
A study of poliomyelitis neutralizing antibodies was carried out on 165 samples of blood serum drawn from subjects aged 14-15 years who had completed vaccination with OPV 11 or 12 years ago. Two different methods of incubation of the serum-virus mixtures (1 hour at 37 degrees C; 6 hours at 37 degrees C and then 18 hours at 4 degrees C, respectively) and two different cell lines (RC-37 and Hep-2) for the inoculation of these mixtures were employed. The results were also evaluated in relation to different initial dilutions of the sera (from 1:4 to 1:1). With the 1:4 initial serum dilution the highest frequencies of sero-negativity were observed utilizing the short incubation time and inoculation in Hep-2 (42% for polio 1, 10% for polio 2, 32% for polio 3). These frequencies diminish significantly utilizing the RC-37 cell line and the long incubation respectively. Under all the experimental conditions the results were better when the 1:2 initial serum dilutions were employed and even better when undiluted sera were used. Neutralizing antibodies against the 3 types of poliovirus were detected in the undiluted sera of all the subjects utilizing the long incubation and inoculation in either the RC-37 or the Hep-2 cell lines. In three subjects lacking detectable antibodies at the 1:4 dilution of the sera, the administration of a dose of IPV produced after 5-7 days a high response which remained almost unchanged 30 days later.
Similar articles
-
Poliomyelitis immunity status at different intervals from vaccination.Eur J Epidemiol. 1986 Sep;2(3):197-204. doi: 10.1007/BF00211532. Eur J Epidemiol. 1986. PMID: 3025013
-
Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.Lancet Infect Dis. 2012 Feb;12(2):128-35. doi: 10.1016/S1473-3099(11)70190-6. Epub 2011 Nov 7. Lancet Infect Dis. 2012. PMID: 22071249 Clinical Trial.
-
Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.Lancet. 1993 Jun 19;341(8860):1545-50. doi: 10.1016/0140-6736(93)90693-b. Lancet. 1993. PMID: 8099637 Clinical Trial.
-
Anomalous observations on IPV and OPV vaccination.Dev Biol (Basel). 2001;105:197-208. Dev Biol (Basel). 2001. PMID: 11763328
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
Cited by
-
Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.Eur J Epidemiol. 1997 Jul;13(5):559-65. doi: 10.1023/a:1007345930234. Eur J Epidemiol. 1997. PMID: 9258569
-
Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to over 15 years before.Eur J Epidemiol. 1996 Feb;12(1):5-8. doi: 10.1007/BF00144420. Eur J Epidemiol. 1996. PMID: 8817170
References
MeSH terms
Substances
LinkOut - more resources
Medical